BioCentury
ARTICLE | Finance

Politicizing science

Why 21st Century Cures is a missed chance for change that will politicize NIH

December 14, 2016 1:50 PM UTC

While the FDA reform provisions in the 21st Century Cures Act give the agency backing to carefully advance some of its long-term objectives, an analysis of the bill’s details suggests that when it comes to NIH, at best the legislation is a missed opportunity to make meaningful changes at the world’s largest biomedical funding agency, leaving long-term problems untouched.

At worst, Cures will be a step backward that will politicize research and skew grant-making toward flashy, short-term translational science projects that are not designed to fill the knowledge gaps that prevent biopharma companies from developing scientific advances into new medicines...

BCIQ Company Profiles

National Institutes of Health